Q-omics provides the consensus-scored WNT5A profile across patient tissues and cancer cell-line models. WNT5A expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, WNT5A is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, WNT5A RNA expression shows 18,968 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, COAD, and UVM as cancer lineages where WNT5A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WNT5A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WNT5A survival associations across molecular data types. WNT5A RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WNT5A RNA expression–survival associations across cancer types. High WNT5A expression shows unfavorable associations in ACC, STAD, LGG and UVM, but favorable associations in COAD and SCLC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for WNT5A RNA expression.
This table summarizes WNT5A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in COAD for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for WNT5A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WNT5A shows lower tumor expression in KIRC and KICH and higher tumor expression in COAD, HNSC, KIRP and THCA. The COAD box plot shows higher WNT5A RNA expression in tumor versus normal tissue (log2 FC = +1.546, t-test p < 0.001).
This table shows molecular features associated with WNT5A in patient tissues and cancer cell lines. In patient samples, WNT5A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, WNT5A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
